Home page500124 • BOM
add
Dr. Reddy's Laboratories
Chiusura precedente
1095,15 ₹
Intervallo giornaliero
1111,50 ₹ - 1142,90 ₹
Intervallo annuale
1025,90 ₹ - 1420,20 ₹
Cap di mercato
931,01Â Mld INR
Volume medio
128.243,00
Rapporto P/E
17,36
Dividendo/Prezzo
0,72%
Borsa valori principale
NSE
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(INR) | dic 2024info | Variazione Y/Y |
---|---|---|
Entrate | 83,59Â Mld | 15,85% |
Spese di gestione | 30,34Â Mld | 19,95% |
Utile netto | 14,13Â Mld | 2,49% |
Margine di profitto netto | 16,91 | -11,51% |
Utili per azione | 16,94 | 1,81% |
EBITDA | 23,43Â Mld | 13,31% |
Aliquota fiscale effettiva | 25,10% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(INR) | dic 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 59,92Â Mld | -17,41% |
Totale attivo | 481,06Â Mld | 29,02% |
Totale passivo | 159,49Â Mld | 51,91% |
Patrimonio netto totale | 321,56 Mld | — |
Azioni in circolazione | 833,12 Mln | — |
Prezzo/valore contabile | 2,87 | — |
Redditività dell'attivo | 9,88% | — |
Rendimento sul capitale | 12,81% | — |
Flusso di cassa
Flusso di cassa netto
(INR) | dic 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 14,13Â Mld | 2,49% |
Liquidità di esercizio | 6,62 Mld | 39,75% |
Contanti da investimenti | -5,46Â Mld | 66,27% |
Contanti da finanziamenti | 590,00Â Mln | -88,83% |
Flusso di cassa netto | 1,75Â Mld | 129,12% |
Flusso di cassa libero | -382,75Â Mln | 90,46% |
Informazioni
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Fondazione
1984
Sito web
Dipendenti
27.048